// App-Quantinova.ai

292 : Safety and Activity of Anti-C1s Humanized Monoclonal Antibody TNT009 in Late Antibody-Mediated Kidney Allograft Rejection – Results of a First-in-Human Phase 1 Trial.

Researchers

Presenter

  • F. Eskandary

Principal Investigators

  • B. Jilma

  • J. Muehlbacher

  • M. Wahrmann

  • H. Regele

  • N. Kozakowski

  • S. Panicker

  • J. Reeve

  • P. Halloran

  • J. Gilbert

  • G. Bohmig

Medical Centers

  • Department of Medicine I, Medical University of Vienna, Austria

  • Department of Urology, Medical University Vienna, Vienna, Austria

  • Department of Urology, Medical University Vienna, Vienna, Austria

  • Department of Urology, Medical University Vienna, Vienna, Austria

  • True North Therapeutics, San Francisco, CA

  • Dpt. of Laboratory Medicine and Pathology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada

Locations

  • Austria

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • TNT009

Outcome

  • N/A

Study Design

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved